Ninety percent of cancer deaths are due to the spread of cancer, not complications from the original tumor. Thus, for over 50 ...
Acceptance and commitment therapy (ACT) significantly decreased fatigue interference and improved quality of life in patients ...
This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast ...
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...
In fact, Tavazoie and colleagues had previously demonstrated that various germline alleles of APOE can enhance or suppress melanoma metastasis. To find out whether breast cancer metastasis operates in ...
Details of the RLY-2608 + fulvestrant poster presentation are as follows: Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- ...
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...
Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), is hosting the 47th ...
On Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA ...
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...
Sharf, MD, and colleagues will discuss treatment considerations in metastatic ER+ breast cancer at the 2024 SABCS meeting.